“It’s fantastic milestone for Senzime to be listed on Nasdaq Stockholm's main market. Senzime is today a global company with its own sales force in US and Germany, we have licensees in Japan and Europe and we have distributors in other important markets. We have delivered hundreds of TetraGraph systems to operating rooms worldwide and new clinical guidelines support our cutting-edge technology that helps eliminate the many millions of anesthesia-related complications that patients experience each year’’, said Pia Renaudin, CEO of Senzime.
The shares will be traded on the Nasdaq Stockholm main market under the same ticker (SEZI) and ISIN-code (SE0002478776). There is no offering or issue of new shares in connection with the list change, and shareholders in Senzime do not need to take any actions.
N.B. English translation is for convenience purposes only.